Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer

被引:7
作者
Djarv, Emma [1 ]
Nyman, Jan
Baumann, Pia
Ekberg, Lars
Hoyer, Morten
Lax, Ingmar
Lewensohn, Rolf
Levin, Nina
Lund, Jo-Asmund
Morhed, Elisabeth
Ericsson, Susanne Rehn
Traberg, Anders
Wittgren, Lena
Johansson, Karl-Axel
机构
[1] Sahlgrenska Univ Hosp, Dept Oncol & Radiat Phys, Gothenburg, Sweden
[2] Karolinska Univ Hosp, Radiumhemmet, Div Oncol & Hosp Phys, Stockholm, Sweden
[3] Aarhus Univ Hosp, Div Oncol & Med Phys, DK-8000 Aarhus, Denmark
[4] Univ Trondheim Hosp, St Olavs Hosp, Trondheim, Norway
[5] Univ Uppsala Hosp, Dept Oncol & Radiol, Uppsala, Sweden
关键词
QUALITY-ASSURANCE;
D O I
10.1080/02841860600919241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In forthcoming multicentre studies on stereotactic body radiotherapy (SBRT) compliance with volume and dose prescriptions will be mandatory to avoid unnecessary heterogeneity bias. To evaluate compliance in a multicentre setting we used two cases from an ongoing phase II study of SBRT of T1-T2N0M0 inoperable NSCLC in a dummy run oriented on volumes and doses. Six Scandinavian centres participated. Each centre received CT-scans covering the whole lung volumes of two patients with instructions to follow the study protocol when outlining tumour and target volumes, prescribing doses and creating dose plans. Volumes and doses of the 12 dose plans were evaluated according to the study protocol. For the two patients the GTV volume range was 24 to 39 cm 3 and 26 to 41 cm(3), respectively. The PTV volume range was 90 to 116 cm(3), and 112 to 155 cm(3), respectively. For all plans the margin between CTV and PTV in all directions followed in detail the protocol. The prescribed dose was for all centres 45 Gy/3 fractions (isocentre dose about 66 Gy). The mean GTV doses ranged from 63 to 67 Gy and from 63 to 68 Gy, respectively. The minimum doses for GTV were between 50 - 64 Gy and between 55 - 65 Gy, respectively. The dose distribution was conformed to PTV for 10 of 12 plans and 2 of 12 plans from one centre had sub-optimal dose distribution. Most of the volume and dose parameters for the participating centres showed fully acceptable compliance with the study protocol.
引用
收藏
页码:973 / 977
页数:5
相关论文
共 10 条
[1]  
Blomgren H., 1998, J RADIOSURGERY, V1, P63, DOI DOI 10.1023/B:JORA.0000010880.40483.C4
[2]   QUALITY ASSURANCE OF THE EORTC RADIOTHERAPY TRIAL-22863 FOR PROSTATIC-CANCER - THE DUMMY RUN [J].
DUSSERRE, A ;
GARAVAGLIA, G ;
GIRAUD, JY ;
BOLLA, M .
RADIOTHERAPY AND ONCOLOGY, 1995, 36 (03) :229-234
[3]  
*INT COMM RAD UN M, 1999, 50 ICRU INT COMM R S
[4]   WORKSHOP OF THE EORTC RADIOTHERAPY GROUP ON QUALITY ASSURANCE IN COOPERATIVE TRIALS OF RADIOTHERAPY - A RECOMMENDATION FOR EORTC COOPERATIVE GROUPS [J].
JOHANSSON, KA ;
HANSON, WF ;
HORIOT, JC .
RADIOTHERAPY AND ONCOLOGY, 1988, 11 (03) :201-203
[5]   TARGET DOSE VERSUS EXTRATARGET DOSE IN STEREOTAXIC RADIOSURGERY [J].
LAX, I .
ACTA ONCOLOGICA, 1993, 32 (04) :453-457
[6]  
Lax I., 1998, Journal of Radiosurgery, V1, P135, DOI [DOI 10.1023/B:JORA.0000010898.87146.2E, 10.1023/B:JORA.0000010898.87146.e, DOI 10.1023/B:JORA.0000010898.87146.E]
[7]  
*RAD THER ONC GROU, 2004, RTOG A PHAS 2 TRIAL
[8]   Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run [J].
Valley, JF ;
Bernier, J ;
Tercier, PA ;
Fogliata-Cozzi, A ;
Rosset, A ;
Garavaglia, G ;
Mirimanoff, RO .
RADIOTHERAPY AND ONCOLOGY, 1998, 47 (01) :37-44
[9]   QUALITY ASSURANCE OF THE EORTC TRIAL 22881/10882 - ASSESSMENT OF THE ROLE OF THE BOOSTER DOSE IN BREAST CONSERVING THERAPY - THE DUMMY RUN [J].
VANTIENHOVEN, G ;
VANBREE, NAM ;
MIJNHEER, BJ ;
BARTELINK, H .
RADIOTHERAPY AND ONCOLOGY, 1991, 22 (04) :290-298
[10]  
*WA U ST LOUIS, 2003, COMP ENV RAD RES CER